Table 2.
Comparison of the prevalence of genotypes for the analyzed polymorphisms in the groups of symptomatic patients, non-symptomatic patients, and control group.
| SNP Gene | N | Genotype | P-value for genotype comparison | Type of comparison |
Dominant model OR (95% CI); p-value |
Recessive model OR (95% CI); p-value |
||
|---|---|---|---|---|---|---|---|---|
| rs4977574 CDKN2B-AS1 | AA (%) | AG (%) | GG (%) | G-risk allele | AG + GG vs. AA | GG vs. AG + AA | ||
| Symptomatic patients | 235 | 61 (25.96) | 112 (47.66) | 62 (26.38) | 0.043 | Symptomatic patients vs. control | 1.40 (0.92-2.11) 0.12 | 1.76 (1.10-2.81); 0.017 |
| Non-symptomatic patients | 171 | 45 (26.32) | 78 (45.61) | 48 (28.07) | 0.031 | Non-symptomatic patients vs. control | 1.37 (0.87-2.15); 0.17 | 1.92 (1.17-3.15) 0.0097 |
| 0.91 | Symptomatic vs. non-symptomatic Patients | 1.08 (0.69-1.68); 0.93 | 0.87 (0.56-1.35); 0.71 | |||||
| Patients in total | 406 | 106 (26.11) | 190 (46.80) | 110 (27.09) | 0.015 | patients in total vs. control | 1.38 (0.95-1.99); 0.08 | 1.83 (1.19-2.80); 0.0055 |
| Control group | 201 | 66 (32.84) | 101 (50.25) | 34 (16.92) | ||||
| rs7857345 CDKN2B-AS1 | CC (%) | CT (%) | TT (%) | C-risk allele | CT + CC vs. TT | CC vs. CT + TT | ||
| Symptomatic patients | 232 | 120 (51.72) | 88 (37.93) | 24 (10.34) | 0.017 | Symptomatic patients vs. control | 1.63 (0.93-2.87); 0.09 | 1.70 (1.16-2.50); 0.006 |
| Non-symptomatic patients | 173 | 83 (47.98) | 79 (45.66) | 11 (6.36) | 0.0099 | Non-symptomatic patients vs. control | 2.77 (1.35-5.68); 0.0041 | 1.47 (0.97-2.21); 0.07 |
| 0.17 | Symptomatic vs. non-symptomatic patients | 0.59 (0.28-1.24); 0.16 | 1.16 (0.78-1.72); 0.46 | |||||
| Patients in total | 405 | 203 (50.12) | 167 (41.23) | 35 (8.64) | 0.0046 | Patients in total vs. control | 1.99 (1.19-3.32); 0.0076 | 1.59 (1.13-2.25); 0.007 |
| Control group | 202 | 78 (38.61) | 92 (45.54) | 32 (15.84) | ||||
| rs3798220 LPA | TT (%) | CT (%) | CC (%) | C-risk allele | CT + CC vs. TT | CC vs. CT + TT | ||
| Symptomatic patients | 238 | 229 (96.22) | 9 (3.78) | 0 (0) | 0.19 | Symptomatic patients vs. control | 0.57 (0.24-1.36); 0.20 | 0.85 (0.02-42.77); 0.93 |
| Non-symptomatic patients | 169 | 153 (90.53) | 7 (4.14) | 9 (5.33) | 0.003 | Non-symptomatic patients vs. control | 1.51 (0.71-3.24); 0.28 | 23.85 (1.38-412.96); 0.0029 |
| 0.0015 | Symptomatic vs. non-symptomatic patients | 0.38 (0.17-0.87); 0.019 | 0.035 (0.002-0.61); 0.02 | |||||
| Patients in total | 407 | 382 (93.86) | 16 (3.93) | 9 (2.21) | 0.044 | Patients in total vs. control | 0.94 (0.47-1.89); 0.88 | 9.6 (0.55-165.9); 0.11 |
| Control group | 201 | 188 (93.53) | 13 (6.47) | 0 (0) | ||||
| rs10455872 LPA | AA (%) | GA (%) | GG (%) | G-risk allele | GA + GG vs. TT | GG vs. GA + AA | ||
| Symptomatic patients | 240 | 213 (88.75) | 27 (11.25) | 0 (0) | 0.39 | Symptomatic patients vs. control | 1.23 (0.66-2.28); 0.52 | 0.28 (0.01-6.93); 0.43 |
| Non-symptomatic patients | 173 | 156 (90.17) | 16 (9.25) | 1 (0.58) | 0.98 | Non-symptomatic patients vs. control | 1.06 (0.53-2.10); 0.88 | 1.17 (0.07-18.92; 0.91 |
| 0.41 | Symptomatic vs. non-symptomatic patients | 1.16 (0.61-2.21); 0.64 | 0.24 (0.01-5.90); 0.38 | |||||
| Patients in total | 413 | 369 (89.35) | 43 (10.41) | 1 (0.24) | 0.73 | Patients in total vs. control | 1.16 (0.66-2.04); 0.62 | 0.49 (0.03-7.88); 0.62 |
| Control group | 203 | 184 (90.64) | 18 (8.87) | 1 (0.49) | ||||
N, number of cases; OR, odds ratio; CI, confidence interval. The bold values are statistically significant.